重视多发性硬化的精准与个体化治疗  

Attach importance to precision and personalized treatment procedures of multiple sclerosis

作　　者：冯金洲[1] 秦新月[1] Feng Jinzhou;Qin Xinyue(Department of Neurology,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院神经内科,重庆400016

出　　处：《中华神经科杂志》2023年第7期721-728,共8页Chinese Journal of Neurology

摘　　要：疾病修正治疗(DMT)是多发性硬化(MS)缓解期的主要治疗方案。自2018年起越来越多DMT药物进入中国,改变着我国MS的治疗现状。但宥于既往长期缺乏DMT药物和MS诊治飞速发展的新进展,导致目前缓解期治疗现状仍欠规范。随着对MS发病机制的深入认识,更多的DMT药物,加上MRI和生物学标志物等对残疾进展和疗效监测手段的增多,MS的治疗策略和治疗目标也在不断改进和提高。基于循证的预后判断、药物及患者相关因素等基础上制定的个体化治疗方案可能是未来MS的主要治疗理念之一。文中结合我国实际情况对此全过程进行评述。Disease-modifying therapy(DMT),the dominating treatment for the remission stage of multiple sclerosis(MS),has reshaped the treatment situation of MS in China due to the increasing number of DMT drugs introduced since 2018.However,the current treatment status is still not satisfied because of the long-time lack of DMT drugs in the past and the latest advances in the diagnosis and treatment of MS.The treatment strategies and goals of MS advanced continuously attributed to the more clarified pathophysiology,more optional DMT drugs and more surveillance methods in disease progression and therapeutic efficacy combined with MRI and biomarkers,etc.Personalized treatment and follow-up protocol established on evidence based prognostication,drug and patient-related factors,probably will be one of the most optimal treatment algorithm in the future.Here is a comprehensive review on how to perform this personalized treatment based on national conditions.

关 键 词：多发性硬化 疾病修正治疗 缓解期 个体化治疗 

分 类 号：R744.51[医药卫生—神经病学与精神病学]